Side-by-side · Research reference
CJC-1295 (no DAC)vsPEG-MGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED15/51 cited
BAnimal-MechanisticHUMAN-REVIEWED2/69 cited
CJC-1295 (no DAC)
Short-acting GHRH · No DAC variant
SQ · Pre-sleep · 1–2×/day
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
01Mechanism of Action
Parameter
CJC-1295 (no DAC)
PEG-MGF
Primary target
Pituitary GHRH receptorTeichman 2006
IGF-1 receptor on muscle satellite cells and myocytes
Pathway
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Downstream effect
Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Feedback intact?
Yes — short pulse preserves somatostatin negative feedbackIonescu 2006
Partially bypassed — does not require hepatic IGF-1 synthesis
Origin
Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Antibody development
Not reported in short-term studies
Unknown — no long-term human immunogenicity data
02Dosage Protocols
Parameter
CJC-1295 (no DAC)
PEG-MGF
Frequency
1–2× daily (pre-sleep ± morning)
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006Ionescu 2006
No-DAC variant is less studied directly; PK extrapolated from native GHRH.
Animal / mechanistic
Duration
8–12 weeks on / 4 off (anecdotal)
—
Reconstitution
Bacteriostatic water
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Timing
Pre-sleep + fasted preferred
Within 30–60 min post-training
Aligns with endogenous MGF window.
Half-life
~30 minIonescu 2006
Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
Research dose range
—
100–200 mcg
Extrapolated from animal models; no validated human protocols.
PEG molecular weight
—
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
03Metabolic / Fat Loss Evidence
Parameter
CJC-1295 (no DAC)
PEG-MGF
Primary target
—
Muscle tissue (satellite cells, myocytes) — not adipose-specific
Indirect metabolic effect
—
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
Body composition
—
Lean mass preservation / hypertrophy focus
Fat loss evidence
—
No direct human or animal RCT data for PEG-MGF-driven fat reduction
04Side Effects & Safety
Parameter
CJC-1295 (no DAC)
PEG-MGF
Injection site reaction
Erythema, mild pruritus
Erythema, induration (common with SQ peptides)
Flushing / headache
Common transient effect
—
Cortisol elevation
Minimal at standard doses
—
Prolactin elevation
Minimal
—
Glucose intolerance
Possible at high cumulative doses
—
IGF-1 elevation
Dose-dependent; monitor with chronic use
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis)
IGF-1 axis stimulation contraindicated in active malignancy
Pregnancy / OB
Avoid
—
Hypoglycemia risk
—
IGF-1 axis activation can lower blood glucose
IGF-1R overstimulation
—
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
Fluid retention
—
Possible with IGF-1 pathway activation (dose-dependent)
PEG accumulation
—
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
Antibody formation
—
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
Human safety data
—
Absent — no published human trials for PEG-MGF
Absolute Contraindications
CJC-1295 (no DAC)
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Relative Contraindications
CJC-1295 (no DAC)
- ·Untreated diabetes
- ·Severe insulin resistance
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
05Administration Protocol
Parameter
CJC-1295 (no DAC)
PEG-MGF
1. Reconstitution
Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites.
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
3. Timing
Pre-sleep preferred. Often combined with ipamorelin in the same syringe.
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
06Stack Synergy
CJC-1295 (no DAC)
+ Ipamorelin
StrongCJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.
- CJC-1295 (no DAC)
- 100 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair